Allogene Therapeutics, Inc. (ALLO)
| Market Cap | 761.91M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -190.89M |
| Shares Out | 343.98M |
| EPS (ttm) | -0.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,903,409 |
| Open | 2.260 |
| Previous Close | 2.250 |
| Day's Range | 2.200 - 2.295 |
| 52-Week Range | 0.862 - 4.460 |
| Beta | 0.54 |
| Analysts | Strong Buy |
| Price Target | 8.35 (+276.98%) |
| Earnings Date | May 7, 2026 |
About ALLO
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for ALLO stock is "Strong Buy." The 12-month stock price target is $8.35, which is an increase of 276.98% from the latest price.
News
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC...
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC...
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the closing of its previously announced underwritten public offering of 87,50...
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC...
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the pricing of an underwritten public offering of 87,500,000 shares of its co...
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced that it intends to offer and sell, in an underwritten public offering and sub...
Allogene Therapeutics Transcript: Study result
Interim analysis of the ALPHA3 trial shows cema-cel achieved a 58.3% MRD clearance rate versus 16.7% for observation, with a favorable safety profile and potential for outpatient use. These results suggest cema-cel could expand CAR T access and redefine first-line large B-cell lymphoma management.
Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics' (NASDAQ: ALLO) interim futility analysis ...
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30% MRD Reduction Occurred Rapidly Following Cema-Cel Treatmen...
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026
SOUTH SAN FRANCISCO, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC...
Allogene Therapeutics Earnings Call Transcript: Q4 2025
Key clinical milestones for ALPHA3 and ALLO-329 are on track for 2026, with pivotal data expected in April and June, respectively. Financial runway extends into Q1 2028, supporting focused execution and expansion into community settings.
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC...
Allogene Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Allogeneic cell therapy programs are advancing with cema-cel targeting MRD-positive large B-cell lymphoma and ALLO-329 in autoimmune diseases. Key milestones include an April futility analysis for cema-cel and proof-of-concept data for ALLO-329 in June 2026, with strong safety and market potential highlighted.
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC...
Allogene Therapeutics Transcript: Citi’s 2026 Virtual Oncology Leadership Summit
The ALPHA3 trial is testing cema-cel, an off-the-shelf CAR T, as a frontline consolidation for large B-cell lymphoma patients with MRD after remission. A 25–30% improvement in MRD clearance is the target for success, with results expected to impact both clinical practice and commercial adoption.
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
Arbitration Ruling Reaffirms Allogene's Full Control of Cemacabtagene Ansegedleucel (Cema-Cel) Decision Reconfirms Allogene's Expanded Sub-License Covering EU and UK Rights with Options for Japan and ...
Allogene Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
Allogeneic cell therapy programs are advancing with a focus on democratizing access and improving cure rates in large B-cell lymphoma, with key interim data expected next year. The autoimmune pipeline, led by ALLO-329, targets both B- and T-cell driven diseases, with initial results anticipated in the first half of next year.
Allogene Therapeutics Transcript: Jefferies London Healthcare Conference 2025
Three clinical programs are advancing, with Cema-Cel leading in MRD-positive lymphoma and a pivotal study targeting a $5B market. Key interim data for Cema-Cel and ALLO-329 are expected in H1 2026, with strong physician and regulatory support for the trial design.
Allogene Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit
ALLO-329, a dual CD19/CD70 CAR T, is in phase I for autoimmune diseases, aiming to reduce or eliminate lymphodepletion for broader use. Early proof of concept data are expected next year. The ALPHA3 lymphoma trial is enrolling globally, focusing on MRD conversion as a key endpoint.
Allogene Therapeutics Earnings Call Transcript: Q3 2025
Advancing scalable cell therapies, the company reported a Q3 net loss of $41.4M and expects pivotal data from cema-cel and Allo329 in 2026. Cash runway extends into H2 2027, with disciplined spending and broad clinical progress across oncology and autoimmune programs.
Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update
Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 Positions Company at the Forefront of MRD-guided, Earli...
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA...
Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update
Conference Call and Webcast Scheduled for November 6, 2025 at 2:00 p.m. PT/5:00 p.m.